Kraig Biocraft's 'Project Atlas' Hits Major Milestone, Targets Industrial & Defense Biomaterials
Summary
Kraig Biocraft Laboratories announced a major milestone in its "Project Atlas" initiative, a next-generation bioengineering program focused on developing new super materials for industrial and defense applications. The company confirmed that Project Atlas has passed its most critical development stage, resulting in the creation of multiple new transgenic lines. This is a significant positive development for KBLB, as it advances its core spider silk technology into potentially high-value markets with enhanced performance capabilities. The breakthrough, described by the CEO as the "most advanced molecular biology work ever undertaken in material science," could reshape the future of biomaterial development. This news, coupled with the company's recent feature on the cover of National Geographic, provides strong validation and increased visibility for Kraig Labs' pioneering work.
At the time of this announcement, KBLB was trading at $0.11 on OTC in the Life Sciences sector, with a market capitalization of approximately $123.7M. The 52-week trading range was $0.07 to $0.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.